United Therapeutics Co. (NASDAQ:UTHR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been given an average rating of “Moderate Buy” by the fifteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $370.86.

UTHR has been the subject of a number of research analyst reports. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. HC Wainwright upped their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 7,796 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84. Following the transaction, the chief financial officer now owns 4,264 shares of the company’s stock, valued at approximately $1,509,626.56. The trade was a 64.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,340 shares of company stock worth $44,765,530. Insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. ClariVest Asset Management LLC raised its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new position in United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC acquired a new stake in United Therapeutics during the 2nd quarter worth approximately $33,000. USA Financial Formulas bought a new position in United Therapeutics during the 3rd quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the third quarter worth approximately $33,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Down 0.7 %

UTHR opened at $367.00 on Thursday. The firm has a market cap of $16.39 billion, a P/E ratio of 16.12, a PEG ratio of 1.07 and a beta of 0.55. The business’s fifty day simple moving average is $369.31 and its 200 day simple moving average is $340.14. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.38 EPS. As a group, equities analysts expect that United Therapeutics will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.